Steve Cardin - UFP Technologies VP MedTech
| UFPT Stock | USD 257.52 3.48 1.37% |
Insider
Steve Cardin is VP MedTech of UFP Technologies
| Address | 100 Hale Street, Newburyport, MA, United States, 01950-3504 |
| Phone | 978 352 2200 |
| Web | https://www.ufpt.com |
Latest Insider Transactions
Steve Cardin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steve Cardin against UFP Technologies stock is an integral part of due diligence when investing in UFP Technologies. Steve Cardin insider activity provides valuable insight into whether UFP Technologies is net buyers or sellers over its current business cycle. Note, UFP Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell UFP Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steve Cardin over six months ago Disposition of 604 shares by Steve Cardin of UFP Technologies at 198.0 subject to Rule 16b-3 |
UFP Technologies Management Efficiency
The company has return on total asset (ROA) of 0.0891 % which means that it generated a profit of $0.0891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1802 %, meaning that it created $0.1802 on every $100 dollars invested by stockholders. UFP Technologies' management efficiency ratios could be used to measure how well UFP Technologies manages its routine affairs as well as how well it operates its assets and liabilities. At this time, UFP Technologies' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.11 in 2025, whereas Return On Capital Employed is likely to drop 0.1 in 2025. At this time, UFP Technologies' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 488 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 5.2 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Reyna Fernandez | iRhythm Technologies | 57 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Joseph Powers | Si Bone | 64 | |
| Michael Favet | Neuropace | 54 | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Janelle Strop | Tactile Systems Technology | N/A | |
| Meghan Scanlon | Paragon 28 | 48 | |
| Victoria Vezina | Rapid Micro Biosystems | 56 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Margaret Carthy | Integer Holdings Corp | 61 | |
| John Glenn | Iradimed Co | 63 | |
| Rebecca Kuhn | Neuropace | 64 | |
| Chad Holman | Varex Imaging Corp | N/A | |
| Shubham Maheshwari | Varex Imaging Corp | 54 | |
| Brice CPA | iRhythm Technologies | 45 | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| MD ODonnell | Tactile Systems Technology | N/A | |
| Steve Deitsch | Paragon 28 | N/A | |
| Erik Mickelson | Paragon 28 | 42 | |
| Lee Rosenthal | Paragon 28 | N/A | |
| Andre Marquette | Neuropace | N/A | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0891 |
UFP Technologies Leadership Team
Elected by the shareholders, the UFP Technologies' board of directors comprises two types of representatives: UFP Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UFP. The board's role is to monitor UFP Technologies' management team and ensure that shareholders' interests are well served. UFP Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UFP Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Bailly, Chairman, CEO and Pres | ||
| Steven Cardin, VP MedTech | ||
| Jeffrey CPA, CEO Chairman | ||
| Mitchell Rock, Sr. VP of Sales and Marketing | ||
| Jason Holt, Chief Officer | ||
| Christopher Esq, Secretary Counsel | ||
| Ronald Lataille, CFO, Sr. VP, Treasurer and Secretary | ||
| Steve Cardin, VP MedTech | ||
| Daniella Mehalik, Vice Finance |
UFP Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UFP Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0891 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 2.19 B | ||||
| Shares Outstanding | 7.67 M | ||||
| Shares Owned By Insiders | 6.70 % | ||||
| Shares Owned By Institutions | 93.30 % | ||||
| Number Of Shares Shorted | 882.47 K | ||||
| Price To Earning | 65.63 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for UFP Stock Analysis
When running UFP Technologies' price analysis, check to measure UFP Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UFP Technologies is operating at the current time. Most of UFP Technologies' value examination focuses on studying past and present price action to predict the probability of UFP Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UFP Technologies' price. Additionally, you may evaluate how the addition of UFP Technologies to your portfolios can decrease your overall portfolio volatility.